Medorb Pharmaceutical Private Limited
About Medorb Pharmaceutical Private Limited
Data last updated:
Medorb Pharmaceutical Private Limited is a private limited company based in Jaipur, Rajasthan, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 05 September 2016 and has been in existence for over 10 years.
The company is registered with the Registrar of Companies (ROC), Jaipur, under CIN U24290RJ2016PTC055894. Its GSTIN is 08AAKCM5711F1ZI (Rajasthan).
The company has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Sharda Devi Meena and Sunil Kumar Kothiwala.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Jaipur, Rajasthan.
As per the financials filed for FY 2025, the company reported a revenue of ₹55,174, a decline of 96% compared to the previous year. For the same year it recorded a net loss of ₹17.64 Lakh and EBITDA of -₹17.36 Lakh. Revenue has declined at a compounded annual rate (CAGR) of 76% over three years and 63% over five years.
The current compliance status is marked as compliant by the Registrar of Companies.
- EmailLocked
- TelephoneLocked
- WebsiteLocked
- Social MediaLocked
- Registered AddressPlot Num 08 First Floor, New Colony Near Railway Line, Jaipur, Rajasthan, India – 302017
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity
The main business activity of Medorb Pharmaceutical is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Financials of Medorb Pharmaceutical Private Limited
FY 2025 filings availableMedorb Pharmaceutical Private Limited reported revenue of ₹55,174 (down 96% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has declined at a compounded annual rate (CAGR) of 63% over five years, including a 96% fall in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2020-21 to FY 2023-24in the company report |
|---|---|---|
| Profit and Loss Statement | ||
| Revenue from Operations | •••• | |
| Other Income | •••• | |
| Total Revenue | •••• | |
| Cost of Materials Consumed | •••• | |
| Employee Benefit Expense | •••• | |
| Finance Costs | •••• | |
| Depreciation and Amortisation | •••• | |
| Other Expenses | •••• | |
| Total Expenses | •••• | |
| EBITDA | -₹17.36 Lakh | |
| Profit Before Tax | •••• | |
| Tax Expense | •••• | |
| Net Profit (PAT) | -₹17.64 Lakh | |
| Balance Sheet | ||
| Share Capital | •••• | |
| Reserves and Surplus | •••• | |
| Net Worth (Total Equity) | •••• | |
| Long-term Borrowings | •••• | |
| Short-term Borrowings | •••• | |
| Trade Payables | •••• | |
| Total Liabilities | •••• | |
| Fixed Assets | •••• | |
| Investments | •••• | |
| Inventories | •••• | |
| Trade Receivables | •••• | |
| Cash and Bank Balance | •••• | |
| Total Assets | •••• | |
Financial Ratios
| Metrics | FY 2024-25 | FY 2020-21 to FY 2023-24in the company report |
|---|---|---|
| Profitability | ||
| EBITDA Margin | •••• | |
| Net Profit Margin | •••• | |
| Return on Equity (ROE) | •••• | |
| Return on Capital Employed (ROCE) | •••• | |
| Return on Assets (ROA) | •••• | |
| Liquidity and Debt | ||
| Current Ratio | •••• | |
| Quick Ratio | •••• | |
| Debt-to-Equity Ratio | •••• | |
| Interest Coverage Ratio | •••• | |
| Efficiency and Growth | ||
| Asset Turnover | •••• | |
| Receivable Days | •••• | |
| Payable Days | •••• | |
| Inventory Days | •••• | |
| Revenue Growth | •••• | |
| Net Profit Growth | •••• | |
Paid data: the figures shown as dots, and every line for FY 2020-21 to FY 2023-24, are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Medorb Pharmaceutical are in the company report.
: available in the company report
Board of Directors of Medorb Pharmaceutical Private Limited
Medorb Pharmaceutical has 2 current directors and 5 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Sharda Devi Meena | Director | 19 Jun 2017 | 9 Years 4 Months | Current |
| Sunil Kumar Kothiwala | Director | 01 May 2021 | 5 Years 5 Months | Current |
Auditor Details
Medorb Pharmaceutical Private Limited is audited by CHOUDHARY GUPTA & CO for the financial year 2018.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| CHOUDHARY GUPTA & CO | Locked | Locked | Locked |
: available in the company report
Ownership and Shareholding
: available in the company report
Charges & Borrowings
Medorb Pharmaceutical Private Limited does not have any charges (loans) registered with the Registrar of Companies.
Employees and EPFO Compliance
Employment history and EPFO contributions of people linked to Medorb Pharmaceutical.
: available in the company report
Recent Activity
Medorb Pharmaceutical Private Limited has 7 board changes on record since 2017: 2 appointments and 5 cessations. The latest: Sunil Kumar Kothiwala was appointed as Director on 01 May 2021.
Credit Ratings, Litigation & Regulatory Alerts
: available in the company report
MSME Payment Delays
: available in the company report
Subsidiaries & Group Companies
: available in the company report
GST Compliance
Medorb Pharmaceutical has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 08AAKCM5711F1ZI | Rajasthan | Active | 01 Jul 2017 |
: available in the company report
MCA Filings & Documents
: available in the company report
Frequently Asked Questions
Medorb Pharmaceutical is an active private limited company based in Jaipur, Rajasthan, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 05 September 2016 (10+ years old) and is registered under CIN U24290RJ2016PTC055894.
Medorb Pharmaceutical has 2 current directors:
- Sharda Devi Meena - Director
- Sunil Kumar Kothiwala - Director
The latest financial statements of Medorb Pharmaceutical on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2017 are in the company report.
The GSTIN of Medorb Pharmaceutical is 08AAKCM5711F1ZI, registered in Rajasthan.
The CIN (Corporate Identification Number) of Medorb Pharmaceutical is U24290RJ2016PTC055894. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Medorb Pharmaceutical was incorporated on 05 September 2016, making it 10+ years old. It is registered with the Registrar of Companies, Jaipur.
Sunil Kumar Kothiwala was appointed as Director on 01 May 2021. Yogendra Sharma ceased to be Director on 01 May 2021. Amit Kumar ceased to be Director on 19 Sep 2019. Medorb Pharmaceutical has 7 board changes on record in total.
The registered office of Medorb Pharmaceutical is at Plot Num 08 First Floor, New Colony Near Railway Line, Jaipur, Rajasthan, India – 302017.
Medorb Pharmaceutical operates in the pharma industry, in the drug formulation and development segment.
The compliance status of Medorb Pharmaceutical is compliant as of 28 August 2026. The company is actively filing with the Registrar of Companies.